x

    Request a Callback

    Fill in your details and our team will get in touch with you.


    Affordable, Targeted Genomic Testing for Precision Oncology in India

    OncoTarget® is a disease-specific targeted NGS panel designed to identify key genomic alterations in major cancers, including Bladder, Breast, Colon, GI, Lung, Melanoma, Ovary, Prostate, Rectal, and Thyroid.

    It offers a practical, affordable solution for guiding personalized therapy decisions in real-world clinical practice.

    Accessible Genomic Insights for Every Patient

    Not every case needs expensive, broad genomic panels.

    OncoTarget® focuses on detecting guideline-recommended, clinically actionable mutations — making precision oncology more accessible, affordable, and easy to implement across India’s healthcare landscape.

    Affordable targeted genomic testing customized to major cancer types

    Deep sequencing of critical disease-specific genes

    Easily understandable reports for quicker treatment planning

    Option to customize up to 20 genes per cancer type

    Optional add-on for PD-L1 expression testing (tissue only)

    Analysis and active reporting powered by the iCare™ AI platform

    How It Works

    1) Disease-Specific Target Capture

    Hybrid capture-based sequencing focused on clinically relevant genes, reducing unnecessary data and cost.

    2 ) Customizable Panel Design

    Ability to customize up to 20 high-priority genes for each cancer type based on clinical need.

    3) AI-Driven Interpretation

    Proprietary AI-based platform simplifies data interpretation, providing clear clinical recommendations aligned with NCCN, ASCO, and ESMO guidelines.

    4) Actionable Reporting

    Reports include tiered variant classification, pharmacogenomics insights (limited to DPYD), and appropriate therapy suggestions.

    Applications

    For Clinicians & Oncology Teams

    • Guide therapy selection based on actionable genomic mutations

    • Improve speed of decision-making for cancer patients

    • Support treatment monitoring and resistance identification

    For Diagnostics Labs & Hospitals

    • Offer cost-effective precision testing solutions
    • Integrate easily into existing pathology and molecular workflows

    Why OncoTarget®?

    Affordable, focused testing designed for India’s clinical settings Customized panels built around the most critical genomic targets Faster, easier-to-interpret reports for guiding precision care Seamless sample collection process with flexible options for tissue or blood

    Specimen Requirements

      
    Sample TypePlasma cDNA (BD PAXgene tube) + optional peripheral blood (K2EDTA) OR 1 FFPE tissue block (20–30% tumor content, ≤ 3–4 months old)
    Sample CollectionPeripheral blood via butterfly needle or 22G syringe
    Sample Volume2 PAXgene tubes + 1 K2EDTA tube OR 1 FFPE block
    cfDNA/DNA Input Amount>1 ng
    Sequencing PlatformIllumina (2 × 150 bp paired-end)
    Mean Sequencing Depth2000x / 10000x
    Sequencing ChemistryHybrid capture
    IndicationsClinically diagnosed cancers associated with OncoTarget® panels
    Analysis PlatformiCare™ AI-based analysis and reporting

    Key Actionable Genes Covered

    Lung

    EGFR, ALK, KRAS, ROS1, MET, RET, HER2, PIK3CA, BRAF

    Breast

    BRCA1, BRCA2, HER2, PIK3CA, ESR1, PALB2

    Colorectal

    KRAS, NRAS, BRAF, ERBB2, PIK3CA, TP53

    Gastrointestinal

    KIT, ALK, KRAS, NRAS, BRAF, ROS1, RET

    Ovary

    BRCA1, BRCA2, MTOR, MSI markers

    Prostate

    BRCA1, BRCA2, CHEK2, PALB2, RAD51D

    Bladder

    FGFR1, FGFR2, FGFR3, HER2, MSI markers

    Melanoma

    BRAF, NRAS, CDKN2A

    Thyroid

    BRAF, ALK, RET, NTRK1/2/3, MSI markers

    1Cell.Ai
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.